Novo Nordisk (NVO)
(Delayed Data from NYSE)
$128.42 USD
-0.24 (-0.19%)
Updated May 10, 2024 04:00 PM ET
After-Market: $128.11 -0.31 (-0.24%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Price, Consensus and EPS Surprise
NVO 128.42 -0.24(-0.19%)
Will NVO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for NVO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NVO
Prothena (PRTA) Q1 Earnings Miss Estimates on Higher R&D Expenses
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
NVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Bulls Look Optimistic About Novo Nordisk (NVO): Should You Buy?
Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
Other News for NVO
U.S. dialysis volumes expected to rebound in 2024 despite GLP-1 impact
One in eight U.S. adults admits to GLP-1 usage as public awareness climbs
One in eight U.S. adults admits to GLP-1 usage as public awareness surges
7 Stocks That Ordinary Investors Can’t Get Enough Of Right Now
EDEN: European Beacon